FlandersBio on Twitter

Follow us on Twitter

Archive for October 2013 - News

Archive for October 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ABLYNX ANNOUNCES UPDATE ON ANTI-RSV NANOBODY PROGRAMME AND RECEIVES GRANT FUNDING FOR FURTHER DEVELOPMENT

31.10.2013

Ablynx [Euronext Brussels: ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company's first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies. read more

Cryo-Save Group N.V.: Management buyout India completed

31.10.2013

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces the completion of its Indian Management Buyout. read more

ABLYNX - PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

31.10.2013

Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Aviva plc and Aviva Investors Global Services Limited. read more

'Pocket'-project ontwikkelt tuberculose-sensor die in je zak past

30.10.2013

Op 1 november 2013 gaat het internationale onderzoeksproject Pocket (Development of a low-cost Point-Of-Care test for Tuberculosis detection) van start. Binnen dit project, dat gecoördineerd wordt door prof. Peter Bienstman van de UGent, wordt een goedkope test ontwikkeld waarmee tuberculose accuraat opgespoord kan worden. read more

ABLYNX'S PARTNER BOEHRINGER INGELHEIM INITIATES PHASE I STUDY WITH NANOBODY TO TREAT ALZHEIMER'S DISEASE

29.10.2013

Ablynx [Euronext Brussels: ABLX] today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer's disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx. read more

ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA ON ALX-0761 AT ACR

28.10.2013

Ablynx [Euronext Brussels: ABLX] today announced that pre-clinical proof-of-concept data from ALX-0761, a Nanobody® partnered with Merck Serono, will be presented at the Annual Meeting of the American College of Rheumatology (ACR), 26 to 30 October 2013, San Diego, California. read more

VIB-UGENT: Why plants usually live longer then animals

25.10.2013

Stem cells are crucial for the continuous generation of new cells. Although the importance of stem cells in fuelling plant growth and development still many questions on their tight molecular control remain unanswered. Plant researchers at VIB and Ghent University discovered a new step in the complex regulation of stem cells. Today, their results are published online in this week’s issue of Science Express. read more

NXT-Dx launches its multiplexed immunoassay service

24.10.2013

NXT-Dx expands its service portfolio with a unique multiplexed immunoassay service, allowing parallel testing of 96 protein markers in 92 samples. The initial assay focuses on cancer markers but additional assays for inflammation and cardiovascular diseases are expected to follow soon. read more

Cardio3 BioSciences krijgt toestemming voor de recrutering van patienten in Italië voor het fase III onderzoek CHART-1

24.10.2013

Het biotechnologiebedrijf Cardio3 BioSciences NV (‘Cardio3’ of de ‘Vennootschap’), een leider in de ontdekking en ontwikkeling van regeneratieve, beschermende en herstellende therapieën voor de behandeling van hartziekten, heeft van de Italiaansegezondheidszorgautoriteit (AIFA) toestemming gekregen voor de start van het CHART-1 onderzoek van zijn behandelingskandidaat C-Cure® in Italië. read more

BIOCARTIS PRESENTS THE SUCCESSFUL USE OF IDYLLATM FOR THE DETECTION OF THE BRAF MUTATION STATUS IN TUMOUR SAMPLES AT THE INTERNATIONAL AACR CONGRESS (AMERICAN ASSOCIATION FOR CANCER RESEARCH) IN BOSTON

23.10.2013

Biocartis also introduces IdyllaTM, the brand name for its innovative and high-quality diagnostic platform (previously codenamed Apollo). IdyllaTM is designed to carry out fast and accurate analysis of a broad range of clinical samples. The platform retains the sensitivity of existing technologies but overcomes, amongst others, the current time-consuming testing process of tumour samples. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print